|
Daehan Nupharm achieved first-quarter sales of 45.6 billion KRW and an operating profit of 7.1 billion KRW
2022.05.13
|
|---|
|
Daehan Nupharm achieved sales of 45.6 billion KRW in the first quarter of 2022, representing a 16% increase compared to the same period of the previous year.
Operating profit rose 7.6% to 7.1 billion KRW, and net profit reached 11.6 billion KRW, a 191% increase year-on-year, driven by a favorable final ruling in a lawsuit resulting in the reversal of approximately 9 billion KRW in litigation reserves.
The human pharmaceuticals division showed strong growth due to increased sales of antibiotics and respiratory disease treatments amid the spread of the Omicron variant, as well as growth in the company's core injectable products. Sales of obesity-related products are rising with the approach of the summer season, supporting expectations of continued growth in the second half.
The animal health division launched the antibiotic tulathromycin and plans to introduce hormone products for pigs, stress relief agents 'Pamdi Zero', and aquatic stress relievers 'Aqua Luthione' in the second half. The company is actively advancing both industrial and companion animal businesses.
Overseas exports are growing with increasing demand for the company's freeze-dried injectable product 'Liporase' beyond Southeast Asia into Latin America and the Middle East. Registrations in Iran and Peru have been recently completed, with the first shipments in March encouraging export growth.
Daehan Nupharm reports balanced growth across all divisions, expecting further expansion through rising overseas demand for injectable products and global market development. |


Home